1.23
Pacific Biosciences Of California Inc stock is traded at $1.23, with a volume of 328.23K.
It is down -3.46% in the last 24 hours and down -18.92% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.28
Open:
$1.24
24h Volume:
328.23K
Relative Volume:
0.03
Market Cap:
$328.64M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.82
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-7.69%
1M Performance:
-18.92%
6M Performance:
-33.70%
1Y Performance:
-71.70%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PACB
Pacific Biosciences Of California Inc
|
1.2301 | 328.64M | 188.87M | -400.38M | -260.90M | -1.50 |
![]()
ABT
Abbott Laboratories
|
125.56 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.62 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
364.33 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
92.16 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
67.80 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-11-24 | Downgrade | UBS | Buy → Neutral |
Jun-03-24 | Resumed | Jefferies | Buy |
Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
Dec-14-23 | Initiated | Guggenheim | Neutral |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
Nov-17-23 | Upgrade | UBS | Neutral → Buy |
Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Jul-05-23 | Resumed | JP Morgan | Overweight |
Jun-30-23 | Initiated | Goldman | Buy |
May-10-23 | Initiated | Barclays | Equal Weight |
Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Feb-02-23 | Initiated | UBS | Neutral |
Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
Jan-06-22 | Resumed | Piper Sandler | Neutral |
Oct-15-21 | Resumed | Cowen | Market Perform |
Sep-27-21 | Initiated | Canaccord Genuity | Buy |
Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
Oct-19-18 | Initiated | Cowen | Outperform |
Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
Sep-28-17 | Downgrade | CL King | Buy → Neutral |
Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
Jun-27-16 | Initiated | CL King | Buy |
Apr-15-16 | Initiated | First Analysis Sec | Overweight |
Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
Feb-04-15 | Reiterated | Maxim Group | Buy |
Sep-26-13 | Reiterated | Maxim Group | Buy |
Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences secures extended lease with rent abatement - Investing.com
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Re - GuruFocus.com
2024 SMRT Conserve grant winners - Pacific Biosciences
Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Selected publications from February 2025 - Pacific Biosciences
Pacific Biosciences COO Mark Van Oene sells $9,125 in company stock - Investing.com Canada
Pacific Biosciences CEO sells $17,583 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO sells $17,583 in stock - Investing.com
ARK Investment Management LLC Buys 2,637,961 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Rare Disease Month: Putting People First - Pacific Biosciences
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know - MSN
Investor Network: Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Chromosome-level genome assembly and improved annotation of onion genome ( Allium cepa L.) - Nature.com
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock - Seeking Alpha
Pacific Biosciences of California's (PACB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $45,776.12 in Stock - MarketBeat
PacBio cut to Neutral at Goldman Sachs after guidance cut - MSN
Revenue Downgrade: Here's What Analysts Forecast For Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Simply Wall St
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14% - Yahoo Finance
Analysts Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
A chromosome-scale reference assembly of Vigna radiata enables delineation of centromeres and telomeres - Nature.com
How HiFi sequencing is making a difference for rare disease research at Children’s Mercy - Pacific Biosciences
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB) - MarketBeat
Pacific Biosciences Executives Conduct Major Stock Transactions - TradingView
Pacific Biosciences Officer Sells Over 259K Shares - TradingView
PacBio to Present at TD Cowen's 45th Annual Health Care Conference on March 4, 2025 - Nasdaq
The Goldman Sachs Group Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50 - MarketBeat
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - Quantisnow
Life sciences stocks fall on NIH funding concerns - MSN
Where Pacific Biosciences Stands With Analysts - Benzinga
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownTime to Sell? - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Announces Quarterly Earnings Results - MarketBeat
StockWatch: NIH Indirect Cost Cuts Shake Tools Stocks - Genetic Engineering & Biotechnology News
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript - Insider Monkey
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday - MarketBeat
PacBio's Strategic Talent Move: 700K Share Package Signals Major Executive Addition - StockTitan
PacBio Grants Equity Incentive Award to New Employee - Quantisnow
PacBio Grants Equity Incentive Award to New Employee - GlobeNewswire Inc.
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Ca - GuruFocus.com
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets Estimates - MarketBeat
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday - Benzinga
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall - Yahoo Finance
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating - Marketscreener.com
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):